Exudative Age-Related Macular Degeneration Clinical Trial
Official title:
Controlled, Double-Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD
The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to LUCENTIS.
The study consisted of a Screening Visit (Visit 1), a Day 0 visit (Visit 2), 6 on-therapy visits at Day 1, Weeks 1, 2, 3, 4, and 8 (Visits 3-8), and an Exit Visit at Week 12 (Visit 9). Patients who met all inclusion and exclusion criteria at Visit 1 were randomized in a 3:1 ratio to receive either AL-78898A or LUCENTIS as a single 50-μL injection in the study eye. Additionally, patients received standard therapy for exudative AMD beginning at Week 2/Visit 5 if the patient was not improving per protocol-specified criteria. Beginning at Week 4/Visit 7, patients not improving received standard therapy for exudative AMD at the investigator's discretion. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01950741 -
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
| Recruiting |
NCT01608113 -
Long-term Follow-up of Subfoveal Neovascular AMD
|
N/A | |
| Completed |
NCT01404845 -
Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation
|
N/A | |
| Completed |
NCT01213082 -
ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01961414 -
Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910
|
Phase 4 | |
| Completed |
NCT01304693 -
ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT01810042 -
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
|
Phase 4 | |
| Completed |
NCT04640272 -
A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
|
Phase 2 | |
| Active, not recruiting |
NCT02976194 -
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
| Completed |
NCT01500915 -
FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration
|
Phase 4 | |
| Enrolling by invitation |
NCT05539235 -
Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD
|
Phase 2/Phase 3 | |
| Completed |
NCT02355028 -
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
|
Phase 2 | |
| Unknown status |
NCT02089503 -
Monocentric Retrospective Observational Study on Patients With Macular Degeneration
|
N/A | |
| Completed |
NCT01796964 -
Efficacy and Safety Study of ESBA1008 Versus EYLEA®
|
Phase 2 | |
| Completed |
NCT01127360 -
LUCAS (Lucentis Compared to Avastin Study)
|
Phase 4 | |
| Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
| Recruiting |
NCT02328209 -
Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
|
N/A | |
| Completed |
NCT01849692 -
ESBA1008 Microvolume Study
|
Phase 2 | |
| Completed |
NCT04138420 -
Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
|
||
| Completed |
NCT03744806 -
Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD
|